‹ Back to publications

Intravenous self-administration evaluation of the possible reinforcing effects of Blue-181 compared with butorphanol and heroin

Blue-181, a non-narcotic, small molecule, binds to a novel CNS drug target. Blue-181 is being developed as an analgesic that will be devoid of the serious side-effects associated with the use of opioid painkillers. One of the most important of these problems is addictive potential.  To investigate the possible reinforcing (rewarding) effects of Blue-181, we determined whether it would maintain self-administration in rats that had been trained to intravenously (i.v.) self-administer heroin. Heroin, a µ-opioid agonist and a Schedule 2 controlled drug (C-II), was selected as the positive control. Saline was the non-reinforcing control. Butorphanol, which is a mixed μ/κ-opioid receptor partial agonist, was the reference comparator. Butorphanol was selected because it has very low potential for human abuse and is not a controlled drug in the UK.

Download

Intravenous self-administration evaluation of the possible reinforcing effects of Blue-181 compared with butorphanol and heroin

Experimental

Abuse & Dependence, CNS

Author

S. Smith, M. Hallam, Z. Turnbull, D. Roberson, M. Painter, A. Yekkirala, D. Heal

Contact us

For more details or information on how we can support your project please complete the contact form.